Shares of Pain Therapeutics (NASDAQ:PTIE) saw an uptick in trading volume on Wednesday . 266,612 shares changed hands during trading, an increase of 98% from the previous session’s volume of 134,503 shares.The stock last traded at $2.29 and had previously closed at $2.40.

Separately, Zacks Investment Research lowered Pain Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, May 4th.

The stock’s market cap is $109.35 million. The stock’s 50 day moving average price is $2.48 and its 200 day moving average price is $2.24.

Pain Therapeutics (NASDAQ:PTIE) last issued its earnings results on Tuesday, July 19th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.07. On average, equities research analysts expect that Pain Therapeutics will post ($0.42) earnings per share for the current year.

Pain Therapeutics, Inc is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company’s lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company’s other products is FENROCK.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.